1. |
Senzolo M Germani G, Cholongitas E, et al. Veno occlusive disease: update on clinical management[J]. World J Gastroenterol, 2007, 13(29): 3918-3924.
|
2. |
Kalayoglu-Besisik S, Yenerel MN, Caliskan Y, et al. Time-related changes in the incidence, severity, and clinical outcome of hepatic veno-occlusive disease in hematopoietic stem cell transplantation patients during the past 10 years[J]. Transplant Proc, 2005, 37(5): 2285-2289.
|
3. |
Mcdonald GB, Sharma P, Matthews DE, et al. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors[J]. Hepatology, 1984, 4(1): 116-122.
|
4. |
Jones RJ, Lee KS, Beschorner WE, et al. Venoocclusive disease of the liver following bone marrow transplantation[J]. Transplantation, 1987, 44(6): 778-783.
|
5. |
Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation[J]. Blood, 1995, 85(11): 3005-3020.
|
6. |
Li CK, Shing MM, Chik KW, et al. Haematopoietic stem cell transplantation for thalassaemia major in Hong Kong: prognostic factors and outcome[J]. Bone Marrow Transplant, 2002, 29(2): 101-105.
|
7. |
Armand P, Kim H, Cutler C, et al. Prognostic impact of elevated pre-transplant serum ferritin in patients undergoing myeloablative stem eell transplantation[J]. Blood, 2007, 109(10): 4586-4588.
|
8. |
Wadleigh M, Richardson PG, Zahrieh D, et al. Prior gcmtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation[J]. Blood, 2003, 102(5): 1578-1582.
|
9. |
Eissner G, Multhoff G, Gerbitz A, et al. Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide[J]. Blood, 2002, 100(1): 334-340.
|
10. |
Chalandon Y, Roosnek E, Mermillod B, et al. Prevention of veno-occlusive disease with defibrotide after allogeneie stem cell transplantation[J]. Biol Blood Marrow Transplant, 2004, 10(5): 347-354.
|
11. |
Dignan F, Gujral D, Ethell M, et al. Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from veno-occlusive disease[J]. Bone Marrow Transplant, 2007, 40(1): 79-82.
|
12. |
董敏, 林曲, 吴祥元, 等. 异基因造血干细胞移植后肝静脉闭塞病的防治效果分析[J]. 癌症, 2008, 27(6): 646-649.
|
13. |
Richardson PG, Soiffer RJ, Antin JH, et al. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial[J]. Biol Blood Marrow Transplant, 2010, 16(7): 1005-1017.
|
14. |
Al Beihany A, Al Omar H, Sahovic E, et al. Successful treatment of hepatic veno-occlusive disease after myeloablative allogeneic hematopoietic stem cell ransplantation by early administration of a short course of methylprednisolone[J]. Bone Marrow Transplant, 2008, 41(3): 287-291.
|
15. |
李兰娟, 黄建容, 陈江华. 人工肝支持系统治疗重型病毒性肝炎的研究[J]. 中华肝病杂志, 1997, 5(4): 202.
|